Shares of Schrödinger surged as much as 10.2% to $18.07 after the computational drug-discovery company posted second-quarter results that flipped a year-ago loss into a profit and paired them with an expanded AI partnership with Bristol Myers Squibb. The question for investors: how much of this quarter was repeatable, and how much was a one-time windfall?

• A $10 Million Milestone Powered the Beat — That Money Doesn't Arrive Every Quarter. Drug-discovery revenue jumped to $23 million in Q2, driven by a $10 million collaboration milestone from Ajax Therapeutics , the oncology partner acquired by Eli Lilly. Net income swung to $6.0 million from a loss of $43.2 million a year earlier. But milestones are lumpy by nature. Management itself flagged dependence on lumpy collaboration milestones as a risk, and analyst consensus still points to negative full-year 2026 earnings per share, with sustained profitability not expected until 2028.

• The Software Business Is Growing, but a Pricing Shift Blurs the Picture. Software annual contract value — the yearly amount customers commit to pay — hit $29.6 million for the quarter, up 27% year over year. Yet hosted revenue reached 47% of software sales versus 31% a year ago, and this shift to cloud-style licensing temporarily pressures reported revenue because those contracts are recognized over time rather than upfront. The transition is strategically sound — recurring revenue is stickier — but it makes headline growth look slower than the underlying demand.

• A Big Pharma AI Deal Validates the Platform, Though Revenue Impact Is Unclear. Schrödinger announced a strategic agreement with BMS to deploy its AI-powered research assistant across BMS's research organization, significantly expanding their long-standing partnership. Winning a top-five pharma company as a flagship user is a credibility boost. Management expects the tool to increase platform usage and expand the user base , but no financial terms were disclosed.

• Raised Guidance Gives a Floor, but the Ceiling Depends on Deals. Full-year drug-discovery revenue guidance was raised to $65–$75 million from $55–$65 million, while annual contract value guidance held at $218–$228 million.

The balance sheet remains solid at $419 million in cash.

Analyst price targets range from $13 to $30 , reflecting deep uncertainty about whether Schrödinger is a software company that deserves a premium or a biotech that burns cash between milestones. This quarter answered that question with "both" — which is exactly why the stock remains volatile.